Itraconazol Tarbis (Itraconazole)

Itraconazole blocks the fungal enzyme lanosterol 14α‑demethylase, a cytochrome P450 isoform, preventing the synthesis of ergosterol. Without ergosterol, the fungal cell membrane becomes defective, leading to inhibited growth and eventual death of the fungus.

The appropriate dose of Itraconazol Tarbis is determined by the prescribing clinician based on the specific infection, patient weight, renal and hepatic function, and other individual factors. Patients should follow the exact regimen provided by their healthcare provider.

Safety data for itraconazole in pregnancy and lactation are limited. It should only be used when the potential benefit to the mother outweighs any possible risk to the fetus or infant, and under close medical supervision.

To place an order, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Compared with fluconazole, itraconazole has a broader spectrum against dimorphic fungi and molds but is more prone to drug‑drug interactions due to CYP3A4 inhibition. It is often preferred for infections where fluconazole activity is limited, such as blastomycosis or certain aspergillosis cases.

Store Itraconazol Tarbis at temperatures below 25 °C in its original packaging, protecting it from moisture and direct sunlight. Keep the product out of reach of children and avoid exposing it to excessive heat or humidity.

Itraconazol Tarbis is taken orally, usually with food or an acidic beverage to improve absorption. The tablet or capsule should be swallowed whole with a full glass of water and not crushed or chewed unless specifically instructed by a healthcare professional.

The most serious adverse events include hepatotoxicity, congestive heart failure, severe skin reactions such as Stevens‑Johnson syndrome, and rare pulmonary toxicity. Patients should be monitored for signs of liver dysfunction, cardiac symptoms, or unusual skin changes during therapy.

Itraconazol Tarbis is contraindicated in individuals with known hypersensitivity to itraconazole or any azole antifungal, in patients with severe hepatic impairment, and in those with established congestive heart failure. Caution is also advised for patients taking drugs that strongly induce CYP3A4.